Merck: encouraging Phase 3 results in esophageal carcinoma

(CercleFinance.com) - Merck said a Phase 3 trial investigating Keytruda in advanced esophageal or esophagogastric junction carcinoma has met a primary endpoint of overall survival.


In this pivotal study, the therapy, which increases the ability of the body's immune system to help fight tumor cells, resulted in a statistically significant improvement in overall survival compared to chemotherapy in patients whose tumors expressed PD-L1.

In a statement, Merck said it was "encouraged" by these results.



Copyright (c) 2018 CercleFinance.com. All rights reserved.